Related Experiment Video
Updated: May 13, 2025

10:21
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
353
Potential Key Genes for Giant Cell Arteritis Revealed Based on Single-Cell Sequencing and Mendelian Randomization
Tao Cheng1,2, Jiafan Chen2, Xinjue Shan1,2
1Beijing University of Chinese Medicine, Beijing, China.
International Archives of Allergy and Immunology
|May 11, 2025
Summary
Giant cell arteritis (GCA) is an autoimmune disease. This study found three genes, RCAN3, RPS6, and HLA-DQB1, causally linked to reduced GCA risk, offering new therapeutic targets.
Area of Science:
- Immunology
- Genetics
- Vascular Biology
Background:
- Giant cell arteritis (GCA) is an autoimmune vasculitis affecting medium to large arteries.
- GCA presents heterogeneously, with potential for serious complications including blindness and aneurysms.
- The underlying pathogenesis of GCA remains incompletely understood.
Purpose of the Study:
- To identify key genes associated with GCA.
- To investigate potential pathogenic mechanisms in GCA development.
- To explore the causal relationship between specific genes and GCA risk.
Main Methods:
- Integrated single-cell RNA sequencing, expression quantitative trait loci (eQTL), and genome-wide association study (GWAS) data.
- Employed two-sample Mendelian randomization (MR) to assess causal effects of CD4+ T cell marker genes on GCA.
- Conducted colocalization analysis to identify shared causal variants.
Main Results:
- Identified RCAN3, RPS6, and HLA-DQB1 as genes causally associated with reduced GCA risk.
- RCAN3 (OR=0.49), RPS6 (OR=0.21), and HLA-DQB1 (OR=0.76) showed inverse associations with GCA.
- Sensitivity analyses confirmed robustness, ruling out heterogeneity, pleiotropy, and reverse causality.
Conclusions:
- Identified RCAN3, RPS6, and HLA-DQB1 as potential key genes in GCA causality.
- These findings offer novel insights into GCA pathogenesis.
- Provides new avenues for developing therapeutic strategies for GCA.

